Supplementary data

Supplemental tables

A/ List of primary antibodies

Target antigen	Vendor or Source	Catalog #	Working concentration	
mouse PECAM-1 (CD31)	BMA Biomedicals	T-2001	2 μg/mL	
mouse PODXL	R&D systems	AF1556	4 μg/mL	
mouse Cy3-anti-smα-actin	Sigma	C6198	5 μg/mL	
mouse NG2	Chemicon	AB 5320		
mouse ACTN2	Sigma	A 2172		
mouse VIM	Cell signaling technology	5741		
mouse ICAM-1 (CD54)	BD Pharmingen	550287	2.5 μg/mL	
mouse VCAM-1	Invitrogen	14-1061-82		
mouse CDH5	R&D systems	AF1002		
mouse FGB	Abcam	ab227063		
mouse COL1A1	Abcam	ab21285		
mouse CX43	Sigma	C6219		
mouse CD41	Proteintech	18308-1-AP	3.5 μg/mL	
mouse Myh7	Atlas antibodies	HPA001239	1 μg/mL	
mouse Desmin	DB Biotech	DB148-0.1	0.5 μg/mL	
mouse CD45	BD Pharmingen	550539	0.625 μg/mL	
mouse CD68	Biolegend	137001	5 μg/mL	
mouse CD3	Santa-Cruz Biotechnology	sc-1127		
mouse B220	R&D systems	MAB1217		
GFP	Novus	NB100-1770SS		
GFP	Invitrogen	A6455		
mouse ATP2A2	Badrilla	A010-80		
phospho-PLN (Ser16)	Badrilla	A010-12		
phospho-PLN (Thr17)	Badrilla	A010-13		
total-PLN	Badrilla	A010-14		
phospho-RYR2 (Ser2814)	Badrilla	A010-31		
α-tubulin	Sigma	T5168		
human CDH5	Cell signaling technology	2500		
human ICAM-1	Santa-Cruz Biotechnology	sc-8439		

B/ List of secondary antibodies


Target antigen	Conjugate	Vendor or Source	Catalog #	Working concentration
Rat IgG	Biotin	Jackson	712-065-153	Dilution 1/500
		ImmunoResearch		
Rabbit	Biotin	Jackson	711-065-152	Dilution 1/500
		ImmunoResearch		
Goat IgG	Alexa Fluor 568	Invitrogen A-11057		10 µg/mL
Rat IgG	Alexa Fluor 647	Invitrogen	A-48265	10 μg/mL
Hamster IgG	Biotin	Jackson	127-065-160	Dilution 1/500
		ImmunoResearch		
Goat IgG	Alexa Fluor 488	Invitrogen A-11055 1		10 μg/mL
Rabbit IgG	Alexa Fluor 488	Invitrogen	A-21206	10 μg/mL
Rabbit IgG	Alexa Fluor 568	Invitrogen	A-10042	10 μg/mL

Supplemental Table 1: List of antibodies used for immunostainings


mouse 18S	F	5'-CGCGGTTCTATTTTGTTGGT-3'
	R	5'-AGTCGGCATCGTTTATGGTC-3'
mouse Col1a1	F	5'-CAACCTCAAGAAGGCCCTGC-3'
	R	5'-TGTCCAAGGGAGCCACATCG-3'
mouse Col3a1	F	5'-AGCACGAGGTCTTGCTGGAC-3'
	R	5'-ACCAGCTGTACCAGGCTGAC-3'
mouse Tgfb1	F	5'-GCTAATGGTGGACCGCAACAAC-3'
	R	5'-CACTGCTTCCCGAATGTCTGAC-3'
mouse Myh7	F	5'-GGATGACGTCACCTCCAACA-3'
	R	5'-AGATCAGAGCCTCCTTCTCGT-3'
mouse Ctgf	F	5'-GACCCAACTATGATGCGAGCC-3'
	R	5'-TCCCACAGGTCTTAGAACAGG-3'
mouse Ttn N-2B	F	5'-ACAGTGGGAAAGCAAAGACATC-3'
	R	5'-AGGTGGCCCAGAGCTACTTC-3'
mouse Ttn N2BA	F	5'-GAGACATTGCTCCGCTTTTC-3'
	R	5'-GATCTCCAAAGAGGCTGTC-3'
mouse Atp2a2 (Serca2a)	F	5'-GATCCTCTACGTGGAACCTTTG-3'
	R	5'-GGTAGATGTGTTGCTAACAACG-3'
human ACTB (β-actin)	F	5'-GGAGGAGCTGGAAGCAGCC-3'
	R	5'-GCTGTGCTACGTCGCCCTG-3'
human ICAM-1	F	5'-ACGCCGGAGGACAGGGCATT-3'
	R	5'-GGGGCTATGTCTCCCCCACCA-3'
human VCAM-1	F	5'-GGCCCAGTTGAAGGATGCGGG-3'
	R	5'-AGAGCACGAGAAGCTCAGGAGAA-3'
human CDH2	F	5'-CCGGTTTCATTTGAGGGCAC-3'
	R	5'-CCCATTGAGGGCATTGGGAT-3'
human IL-6	F	5'-GAAGATTCCAAAGATGTAGCCGC-3'
	R	5'- GGTTGTTTTCTGCCAGTGCCTC-3'

Supplemental Table 2: List of primers used for reverse transcription (RT) quantitative polymer chain reaction (qPCR). F: forward; R: reverse


Supplemental figures and figure legends




Supplemental Figure 1: (A-B): Pdgfrb-Cre/ERT2; Rosa-mTmG mice were administered with tamoxifen and sacrificed 7 days after the first injection. (A) Heart cross sections were immunostained with anti-GFP antibodies (in brown). (B) Heart cross sections were co-immunostained with anti-GFP antibodies (in green) together with anti-NG2 antibodies (in red) to identify pericytes or anti-SMA (in red) and anti-PODXL antibodies (in white) to identify SMCs and endothelial cells respectively.




Supplemental Figure 2: Pdgfrb-Cre/ERT2; Rosa-mTmG mice were administered with tamoxifen and sacrificed 7 days after the first injection. (A) Tissue sections were immunostained with anti-GFP antibodies alone or together with anti-SMA antibodies to identify SMCs or anti-NG2 antibodies to identify pericytes.




Supplemental Figure 3: Pdgfrb-Cre/ERT2; RosaDTA (Pdgfrb-DTA) mice were administered with tamoxifen. Mice were sacrificed 7 days (**A**) or 28 days after the first injection (**B**). Heart cross sections were co-immunostained with anti-NG2 antibodies (in red) together with anti-PODXL antibodies (in green), the percentage of NG2 positive vessel was counted. **: $p \le 0.01$, ***: $p \le 0.001$ (Mann Whitney test).




Supplemental Figure 4: Pdgfrb-Cre/ERT2; RosaDTA (Pdgfrb-DTA)mice were administered with tamoxifen and sacrificed 28 days after the first injection. Tissues sections were staining with Masson's trichrome stain, anti-SMA or anti-NG2 antibodies.




Supplemental Figure 5: Pdgfrb-Cre/ERT2; RosaDTA (Pdgfrb-DTA) and RosaDTA (Control) mice were administered with tamoxifen. Mice were sacrificed 28 days after the first injection. (A) The weight of mice was measured and (B) correlated with pericyte coverage. (C) Hemoglobin content, (D) white blood cells count and platelet count (E) was calculated in total blood samples. (F) Triglycerides, (G) total cholesterol, (H) proteins, (I) Aspartate aminotransferase (AST), (J) Alcaline phosphatase (ALP) and (K) urea levels were measured in plasma samples. (L) Heart rate, (M) systolic, (N) diastolic and (O) mean blood pressures were measured via left ventricular catheterization. (P) Exercise tolerance on a treadmill was assessed. *: p≤0.05, ***: p≤0.001, ns: not significant (Mann Whitney test).




Supplemental Figure 6: Pdgfrb-Cre/ERT2; RosaDTA (Pdgfrb-DTA) and RosaDTA (Control) mice were administered with tamoxifen. Mice were sacrificed 28 days after the first injection. (**A**) Heart cross sections were stained with Sirius red to identify fibrosis. (**B**) Interstitial fibrosis was quantified using Image J software (n=9 and 11). (**C**) Perivascular fibrosis was quantified using Image J software (n=9 and 11). (**C**) Perivascular fibrosis was quantified by RT-qPCR in total heart extracts and normalized to 18S rRNA. *: p≤0.05, ns: not significant (Mann Whitney test).



Supplemental Figure 7: Cardiac HMVECs were co-cultured or not with mouse cardiac pericyte. Each cell type was plated on each side of a 0.4 μ m pored Transwell[®] membrane for 48 hours. (**A**) Pericytes were immunostained with anti-NG2 antibodies in green, HMVECs were immunostained with anti-CDH5 antibodies in red. (**B**) CDH5 protein level in HMVECs was evaluated via western blot analysis and (**C**) quantified using Image J software. *CDH2* (**D**), *IL-6* (**E**), *ICAM-1* (**F**) and *VCAM-1* (**H**) mRNA levels were quantified via RT-qPCR and normalized to *ACTB* mRNA. (**I**) ICAM-1 protein level in HMVECs was evaluated via western blot analysis and (**J**) quantified using Image J software. *: p≤0.05, **: p≤0.01 (Mann Whitney test).



Supplemental Figure 8: Pdgfrb-Cre/ERT2; RosaDTA (Pdgfrb-DTA) and RosaDTA (Control) mice were administered with tamoxifen. Mice were sacrificed 28 days after the first injection. (**A**) *II-6* mRNA level was quantified via RT-qPCR and normalized to 18S rRNA. (**B**) Heart cross sections were co-immunostained with anti-CD45 antibodies (in green) and anti-ACTN2 antibodies (in red). (**C**) The number of CD45 positive leucocytes/mm² was quantified using Image J software. (**D**) Heart cross sections were co-immunostained with anti-CD68 antibodies (in green) and anti-desmin antibodies (in red). (**E**) The number of CD68 positive macrophages/mm² was quantified using Image J software. (**F**) Heart cross sections were co-immunostained with anti-CD3 antibodies (in green) and anti-desmin antibodies (in red). (**G**) The number of CD3 positive T-lymphocytes/mm² was quantified using Image J software. (**H**) Heart cross sections were co-immunostained with anti-B220 antibodies (in green) and anti-desmin antibodies (in red). (**I**) The number of B220 positive B-lymphocytes/mm² was quantified using Image J software. *: $p \le 0.05$, ***: $p \le 0.001$, ns: not significant (Mann Whitney test).



Supplemental Figure 9: Human cardiac myocyte (HCM) were co-cultured or not with mouse cardiac pericytes. Each cell type was plated on each side of a 0.4 μm pored Transwell[®] membrane for 48 hours. (**A**) ATP2A2 protein level in HCMs was evaluated via western blot analysis and (**B**) quantified using Image J software. (**C**) CX43 protein level in HCMs was evaluated via western blot analysis and (J) quantified using Image J software. ns: not significant (Mann Whitney test).